Optics
← Today's headlines

2 sources checked · 2 source groups included · 1h ago

Still Watching

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

One headline uses the stronger term "Rejects" and highlights the drug as "Closely Watched," while the other states "Doesn't Approve."

1 Left0 Center1 Right
Still watching. Optics is waiting for a cleaner match before calling the split.

STILL WATCHING

As of November 15, 2026 at 8:33 PM, this is how Optics News reads the wording differences in this story.

What happened The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.
The headline split The left frames it as "F.D.A. Rejects Closely Watched Lung Cancer Drug From China". The right frames it as "FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug".
Match confidence Developing. The source map is still developing. Keep watching for more sources to join.
Same-event confidenceDeveloping

Not enough sources yet to confirm this is the same specific event.

WHAT EACH SIDE EMPHASIZED

Left / center-leftF.D.A. Rejects Closely Watched Lung Cancer Drug From China

New York Times - Business · Center-left · News report

CenterNo matching source in this bucket yet.

Optics keeps watching for pickup.

Right / center-rightFDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

Investor's Business Daily · Center-right · News report

SEE THE HEADLINES

Center-rightMostly Factual
Investor's Business DailyNews report · Nov 15, 7:34 PM

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

Doesn't Approve

The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.

Open source
Center-leftMostly Factual
New York Times - BusinessNews report · Nov 15, 8:33 PM

F.D.A. Rejects Closely Watched Lung Cancer Drug From China

RejectsClosely Watched

The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.

Open source
Details45/99 Wording Gap · Low confidence · 2 sources
45/99 Wording GapLow confidence2 sources · 2 bias bucketsDeveloping · 2 sources · 2 bucketsFormats: News report

SOURCE MAP CHANGES

Nov 15, 7:34 PM: Investor's Business Daily joined the source map.

Nov 15, 8:33 PM: New York Times - Business joined the source map.

Now: Wording Gap is 45/99 and story health is developing · 2 sources · 2 buckets.